InvestorsHub Logo
icon url

PeterKarol

10/06/17 2:42 PM

#123398 RE: camk #123391

Dr D likes to play hide and seek with shareholders. The stock buying program and the removal of perfectly viable programs from pipeline illustration squares with each other. I don't know much about MS but epilepsy murine models predict hitting 10 so when others not validated to that degree are still their and those two disappeared then there is something afoot. How you remove what was validated at the level of mutineers model without proving it moot in human trials which are the next step. Either this or Dr M is off the deep end. Call ambulance!
icon url

seventhwave

10/06/17 8:12 PM

#123422 RE: camk #123391

notion that there is no deal as speculated and hoped by many


I think you're right. The new timeline chart serves to clean up and focus on the 3 impending trials.
Clean up, because a pathway for "Epilepsy" in the old pipeline was too generalized - as dadofM&M pointed out AVXL will initially target the genetic syndromes involving epileptic condition like Rett, Angelman syndrome, fragile x syndrome, Lennox-gastaut syndrome FIRST. Conditional on success, AVXL will then target focal (partial onset seizures) epilepsy and idiopathic and/or symptomatic generalized epilepsy (terminologies borrowed from dadofM&M). So you see, it didn't make sense to have just one pipeline pathway labeled "Epilepsy" and now AVXL is being SPECIFIC.
In the old chart, I had no idea what the pathway labeled "Cognition in Neuropsychiatric (Disorders)" was all about - it may have been a generalized placeholder for specific trials to come. Now it's gone - probaby means they will be addressed much later.
Dropping MS is certainly odd as work has been ONGOING and in the forefront although preclinical. Maybe there are no plans to start clinical work in the near future unless a sponsor steps up as they certainly don't have funds for it - no funds = no plan timeline. Not good enough reason to drop it though as other compounds/indications remain on the chart. Baffling move to say the least but impending (BIIB) outlicense couldn't have prompted it as it would be an uncalled for manoeuver and an unjustified omission.